1
SPONSORED SYMPOSIUM
2
SalaSinopoli
TeatroStudio
08.00 - 09.00TEVA SYMPOSIUMNon CME Session
10.00 - 11.00ELI-LILLY SYMPOSIUM
Non CME Session
14.30 - 15.30CEFALY TECHNOLOGY SYMPOSIUM
Non CME Session
SalaSinopoli
08.00 - 09.00NOVARTIS SYMPOSIUM
Non CME Session
11.30 - 12.30ALLERGAN SYMPOSIUM
Non CME Session
TimetableFriday, 1 December 2017
TimetableSaturday, 2 December 2017
3
Friday, 1 December 2017
Sala Sinopoli
08:00 - 09:00 TEVA SYMPOSIUM - Non CME Session
CGRP IN MIGRAINE PREVENTION: IMPACT, RATIONALE, AND IMPLICATIONS
Symposium Chairman: Professor Paolo Martelletti, MD, PhD
Speakers and Specific Subtitles:
Messoud Ashina, MD, PhD: Public Health Impact of Migraine in Europe
Cristina Tassorelli, MD, PhD: Appropriate Patients for Migraine
Prevention and Issues with Persistence and Adherence on Current Standard of Care
Rami Burstein, PhD: CGRP and Migraine Pathophysiology
Teatro Studio
10:00 - 11:00 ELI-LILLY SYMPOSIUM - Non CME Session
A TARGETED APPROACH TO MIGRAINE
10.00 - 10.10 Welcome and introduction - Paolo Martelletti MD (Italy)
10.10 - 10.30 Do we need any more treatments for acute migraine? - Antoinette Maassen van den
Brink, PhD (The Netherlands)
10.30 - 10.50 A targeted approach to preventing migraines and the elevated expectations
on response rates - Patricia Pozo-Rosich, MD, Phd (Spain)
10.50 - 11.00 Panel discussion and questions and answers, closing remarks - All
14:30 - 15:30 CEFALY TECHNOLOGY SYMPOSIUM - Non CME Session
E-TNS IN THE TREATMENT OF MIGRAINE
14.30 - 14.40 Introduction: rational, technology and parameters (Stephen Silberstein)
14.40 - 14.55 Efficacy in migraine prevention (Antonio Russo)
14.55 - 15.10 Efficacy in migraine attack treatment (Jean Schoenen)
15.10 - 15.20 Mechanisms of action (Gianluca Coppola)
15.20 - 15:30 Q&A -
Chairman: Marina de Tommaso
Moderator: Paolo Martelletti
4
Saturday, 2 December 2017
Sala Sinopoli
08:00 - 09:00 NOVARTIS SYMPOSIUM - Non CME Session
TARGETING MIGRAINE BY DESIGN – NEW TREATMENT APPROACHES TO SHAPE FUTURE PATIENT CARE
Chair: Andreas Gantenbein (RehaClinic, Bad Zurzach, Switzerland)
08.00 - 08.05 Welcome and introduction
08.05 - 08.20 Is there a need for new prophylactic treatments of migraine? (Interactive debate)
Moderator: Andreas Gantenbein (RehaClinic, Bad Zurzach, Switzerland)
08.20 - 08.35 Rethinking migraine management - Cristina Tassorelli (Università degli Studi di Pavia, Italy)
08.35 - 08.50 Targeting the underlying biology of migraine - Lars Edvinsson (Lund University, Sweden)
08:50 – 09.00 Closing remarks - Andreas Gantenbein (RehaClinic, Bad Zurzach, Switzerland)
11:30 - 12:30 ALLERGAN SYMPOSIUM - Non CME Session
BOTULINUM TOXIN TYPE A: NEW INSIGHTS INTO TREATMENT OF CHRONIC MIGRAINE FROM EMERGING DATA.
Chair: Paolo Martelletti (Italy)
11.30 - 11.40 Welcome and introductions
Overview of most recent real world data - Paolo Martelletti, Italy
11.40 - 12.00 Understanding chronic migraine: the pathophysiology and how botulinum toxin type
A works to help relieve the burden of this condition - Rami Burstein, US
12.00 - 12.25 The FORWARD study: results of a head-to-head comparison of botulinum toxin type
A versus topiramate for the treatment of chronic migraine - Andrew Blumenfeld, US
12.25 - 12.30 Wrap-up and closing